Will our cardiomyopathy patients accept gene therapy?
Publication date
2022-07
Authors
Doevendans, Pieter
Kupatt, C.
Giacca, M.
Glijnis, P.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by
Abstract
Novel techniques such as gene therapy are becoming available in an attempt to cure inherited diseases. Before these new therapies can be offered to patients, we need to be aware of potential reservations or objections, not only from patients and their surroundings but also from the public. In addition, legal issues and costs need attention before curative gene therapy can be applied in the clinic. As this therapeutic approach is closer to becoming a reality, now is the right time to start the debate.
Keywords
Cardiomyopathy, Gene editing, Viral vectors, Cardiology and Cardiovascular Medicine
Citation
Doevendans, P A, Kupatt, C, Giacca, M & Glijnis, P 2022, 'Will our cardiomyopathy patients accept gene therapy?', Netherlands Heart Journal, vol. 30, no. 7-8, pp. 343-344. https://doi.org/10.1007/s12471-022-01665-z